AGC Biologics Wins Three Cell Therapy Projects In Japan

KUALA LUMPUR, Nov 18 (Bernama) -- AGC Biologics, a global biopharmaceutical contract development and manufacturing organisation, has been selected by three biopharma developers, including the Institute of Science Tokyo, to provide cell therapy services at its Yokohama facility.

The facility, which began offering cell therapy services in July 2025, combines the company's 30 years of experience at its Milan site with the AGC Group's more than 100 years of manufacturing expertise in Japan.

Its services include process transfer and manufacturing for pre-clinical and clinical trials, covering technologies such as induced pluripotent stem cells, mesenchymal stem cells, haematopoietic stem cells, exosomes and CAR-T cell therapies.

Ad Banner
Ad Banner

One of the projects involves research led by the Institute of Science Tokyo to advance third-party virus-specific T-cell therapy towards clinical application for treatment-resistant adenovirus infections following haematopoietic cell transplantation.

AGC Biologics in a statement said it will support the research through process development and analytical method development to facilitate future clinical and manufacturing implementation.

Another project involves transferring a customer programme from AGC Biologics' Milan facility to Yokohama for further development and manufacturing, supported by coordination across the company's global network.

Ad Banner
Ad Banner
Ad Banner

The company's Cell and Gene Technologies Division has supported customers in securing 18 commercial approvals for their products through its development and manufacturing services.

-- BERNAMA